Detail akcie Swe Orphan Biovitru online

Business Summary: Swedish Orphan Biovitrum AB (publ) is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The Company has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Swedish Orphan Biovitrum AB (publ) revenues increased 3% to SEK6.47B. Net income increased 9% to SEK875M. Revenues reflect Haematology segment increase of 14% to SEK4.63B, Specialty Care segment increase of 13% to SEK306M. Net income benefited from Net financial items decrease of 21% to SEK262M (expense), Other operating income/expenses decrease of 25% to SEK6M (expense).